Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics

Completed

Conditions studied: Arthritis, Rheumatoid

In brief

To compare rheumatoid arthritis (RA) patient characteristics, adherence, and costs between patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs.

Key facts

Study ID

NCT03964649

Run by

Pfizer

People needed

7308

Starts

2019-01-01

Expected to finish

2020-04-06

Last updated by the study team

2021-06-02

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least one claim for methotrexate during the variable-length pre-index period.
• At least one claim for tofacitinib or bDMARDs between 01 February 2016 and 31 July 2019 (the identification period).

You may not qualify if…

• Patients with claims for other conditions for which bDMARDs are used during the one-year pre-index period or on the index date: ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, or ulcerative colitis will be excluded from the study.
• Patients with evidence of the index medication during the one-year pre-index period will be removed from the analysis. Patients will be allowed to have been treated with (other) bDMARDs during the one-year pre-index period.
• Patients with more than 1 bDMARD or bDMARD with tofacitinib filled on the index date will be removed from the study.

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.